Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors

TW Vanderah, RN Bernstein, HI Yamamura, VJ Hruby and F Porreca

Department of Pharmacology, University of Arizona Health Science Center, Tucson, USA.

This study investigated the possible involvement of opioid delta receptors in the modulation of morphine antinociceptive potency produced by L365,260 a CCKB antagonist. Intracerebroventricular (i.c.v.), intratheoal (i.th.) or subcutaneous (s.c.) L365,260 alone did not produce any antinociceptive actions in the mouse warm-water tail- nick test. Treatment with L365,260 by any of these routes produced a leftward shift of the corresponding morphine dose-effect curve that was blocked by pretreatment with a receptor selective dose of s.c. naltrindole, an opioid delta receptor antagonist. Pretreatment with i.c.v. antisera to [Leu5]enkephalin also blocked the leftward displacement of the i.c.v. morphine dose-effect curve resulting from L365,260 but did not directly alter the i.c.v. morphine dose-effect curve; antisera to [Met5]enkephalin did not alter the effects of morphine or the modulation of morphine antinociception produced by L365,260. Repeated pretreatment with L365,260 resulted in a progressive decrease in the magnitude of the morphine modulatory action (i.e., L365,260 "tolerance"). In these "L365,260-tolerant" mice, the dose- effect curve for i.c.v. [D-Ala2, Glu4]deltrophin (a selective delta agonist) was displaced to the right by approximately 8.2-fold. The i.c.v. administration of [Leu5]enkephalin produced a leftward displacement of the i.c.v. morphine dose-effect curve that diminished after repeated administration (i.e., [Leu5]enkephalin "tolerance"). In "[Leu5]enkephalin-tolerant" mice, L365,260 failed to produce the leftward shift of the morphine dose-effect curve seen in control animals. That is, two-way antinociceptive cross-tolerance was observed between an opioid delta agonist and a CCKB receptor antagonist. Intracerebroventricular thiorphan, a peptidase inhibitor, did not elicit antinociception directly. Co-administration of thiorphan with L365,260 elicited significant antinociception that was blocked by naltrindole or antisera to [Leu5]enkephalin; antisera to [Met5]enkephalin had no effect. Repeated administration of i.c.v. [D- Ala2, Glu4]deltorphin resulted in a progressively decreasing antinociceptive effect (i.e., [D-Ala2, Glu4]deltorphin "tolerance"). In "[D-Ala2, Glu4]deltorphin-tolerant" mice, the thiorphan/L365,260 antinociceptive effect was inhibited. Collectively, these data suggest that CCK interacts at the CCKB receptor to inhibit tonically the release and/or availability of an endogenous substance acting at opioid delta receptors. The subsequent enhancement of morphine antinociceptive potency may reflect the well-known modulation of morphine antinociception produced by opioid delta receptor agonists. In this case, the latter may be [Leu5]enkephalin or a [Leu5]enkephalin-like substance.

Volume 278, Issue 1, pp. 212-219, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Y. Xie, D. S. Herman, C.-O. Stiller, L. R. Gardell, M. H. Ossipov, J. Lai, F. Porreca, and T. W. Vanderah Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance J. Neurosci., January 12, 2005; 25(2): 409 - 416. [Abstract] [Full Text] [PDF]

				G.-M. Zhao, D. Wu, Y. Soong, M. Shimoyama, I. Berezowska, P. W. Schiller, and H. H. Szeto Profound Spinal Tolerance after Repeated Exposure to a Highly Selective {micro}-Opioid Peptide Agonist: Role of delta -Opioid Receptors J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 188 - 196. [Abstract] [Full Text] [PDF]

				J. J. Rady, B. B. Holmes, L. F. Tseng, and J. M. Fujimoto Inverse Agonist Action of Leu-Enkephalin at delta 2-Opioid Receptors Mediates Spinal Antianalgesia J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 582 - 589. [Abstract] [Full Text]

				M. M. Heinricher, S. McGaraughty, and V. Tortorici Circuitry Underlying Antiopioid Actions of Cholecystokinin Within the Rostral Ventromedial Medulla J Neurophysiol, January 1, 2001; 85(1): 280 - 286. [Abstract] [Full Text] [PDF]

				A. E. Friedrich and G. F. Gebhart Effects of Spinal Cholecystokinin Receptor Antagonists on Morphine Antinociception in a Model of Visceral Pain in the Rat J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 538 - 544. [Abstract] [Full Text]